Daiichi Sankyo Withdraws Shipment Of Half The Company's Entire Influenza Vaccine Supply
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Daiichi Sankyo Co. Ltd. will trash nearly half of its annual influenza vaccines after tests revealed batches were contaminated by avian reovirus. The company's joint venture with Kitasato Institute for vaccine production has had a rocky start since it began operations March 31, but vaccines play a small role in the company's overall domestic sales, so impact is expected to be negligible